73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
As cancer deaths decline, access to care remains a challenge in some US communities

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th
Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa
One-cycle cisplatin seems safe for high-risk early testicular cancer

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m
Australia on track to be the first country to eliminate cervical cancer, but inequities persist

Australia on track to be the first country to eliminate cervical cancer, but inequities persist

by Dr Tessa Saunders, Dr Claire Nightingale, Associate Professor Megan Smith and Claire Bavor,University of MelbourneSelf-screening for HPV is one way to remove barriers to screening. Credit: Au

Australia on track to be the first country to eliminate cervical cancer, but inequities persist

by Dr Tessa Saunders, Dr Claire Nightingale, Associate Professor Megan Smith and Claire Bavor,University of MelbourneSelf-screening for HPV is one way to remove barriers to screening. Credit: Au
Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK
Researchers identify potential formula for blood cancer vaccine

Researchers identify potential formula for blood cancer vaccine

byThe Mount Sinai HospitalMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Researchers at the Icahn School of Medicine at

Researchers identify potential formula for blood cancer vaccine

byThe Mount Sinai HospitalMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Researchers at the Icahn School of Medicine at
New technology in recent clinical study aims toward earlier detection of hepatocellular carcinoma

New technology in recent clinical study aims toward earlier detection of hepatocellular carcinoma

byUniversity of California, Los AngelesCredit: Pixabay/CC0 Public DomainPrimary liver cancer, the third-leading cause of cancer-related death worldwide, takes more than 30,000 lives in the Unite

New technology in recent clinical study aims toward earlier detection of hepatocellular carcinoma

byUniversity of California, Los AngelesCredit: Pixabay/CC0 Public DomainPrimary liver cancer, the third-leading cause of cancer-related death worldwide, takes more than 30,000 lives in the Unite
Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer
Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na
Acute leukemia patients treated with common therapy have increased risk for heart failure

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh
Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumorsby Olivia Dimmer,Northwestern UniversityMultiplex immunofluorescence staining and imaging using the COMET system platform on a human meningiom

Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumorsby Olivia Dimmer,Northwestern UniversityMultiplex immunofluorescence staining and imaging using the COMET system platform on a human meningiom
Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe